The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enable...

Full description

Bibliographic Details
Main Authors: Shabbir Ahmed, Zhan Zhou, Jie Zhou, Shu-Qing Chen
Format: Article
Language:English
Published: Elsevier 2016-10-01
Series:Genomics, Proteomics & Bioinformatics
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1672022916301413
id doaj-19fa756467a2427c9ba3208fcfa8d331
record_format Article
spelling doaj-19fa756467a2427c9ba3208fcfa8d3312020-11-25T01:06:25ZengElsevierGenomics, Proteomics & Bioinformatics1672-02292016-10-0114529831310.1016/j.gpb.2016.03.008Shabbir Ahmed0Zhan Zhou1Jie Zhou2Shu-Qing Chen3Department of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaDepartment of Precision Medicine and Biopharmaceutics, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, ChinaThe interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.http://www.sciencedirect.com/science/article/pii/S1672022916301413PharmacogenomicsPrecision medicineGenetic polymorphismPhase-I drug-metabolizing enzymesDrug transporters
collection DOAJ
language English
format Article
sources DOAJ
author Shabbir Ahmed
Zhan Zhou
Jie Zhou
Shu-Qing Chen
spellingShingle Shabbir Ahmed
Zhan Zhou
Jie Zhou
Shu-Qing Chen
Genomics, Proteomics & Bioinformatics
Pharmacogenomics
Precision medicine
Genetic polymorphism
Phase-I drug-metabolizing enzymes
Drug transporters
author_facet Shabbir Ahmed
Zhan Zhou
Jie Zhou
Shu-Qing Chen
author_sort Shabbir Ahmed
publisher Elsevier
series Genomics, Proteomics & Bioinformatics
issn 1672-0229
publishDate 2016-10-01
description The interindividual genetic variations in drug metabolizing enzymes and transporters influence the efficacy and toxicity of numerous drugs. As a fundamental element in precision medicine, pharmacogenomics, the study of responses of individuals to medication based on their genomic information, enables the evaluation of some specific genetic variants responsible for an individual’s particular drug response. In this article, we review the contributions of genetic polymorphisms to major individual variations in drug pharmacotherapy, focusing specifically on the pharmacogenomics of phase-I drug metabolizing enzymes and transporters. Substantial frequency differences in key variants of drug metabolizing enzymes and transporters, as well as their possible functional consequences, have also been discussed across geographic regions. The current effort illustrates the common presence of variability in drug responses among individuals and across all geographic regions. This information will aid health-care professionals in prescribing the most appropriate treatment aimed at achieving the best possible beneficial outcomes while avoiding unwanted effects for a particular patient.
topic Pharmacogenomics
Precision medicine
Genetic polymorphism
Phase-I drug-metabolizing enzymes
Drug transporters
url http://www.sciencedirect.com/science/article/pii/S1672022916301413
_version_ 1725190333348708352